Therapeutic Area Focus for Researchers

Guidance for developing high-impact APR.Intern project proposals

To help ensure Expressions of Interest are aligned with CSL's areas of therapeutic interests, applicants should demonstrate how their proposed internship project could contribute to advancing diseases within one or more of the therapeutic areas listed below.

Projects are not expected to directly develop new medicines. However, strong applications will clearly articulate how the research could advance scientific knowledge, for example: uncover disease mechanisms, identify biomarkers, improve patient stratification, generate translational insights, support clinical development, or address an important unmet medical need within these areas.

The examples below are intended to provide context and guidance.

What we are looking for: Projects addressing substantial unmet need, aligned with strategic therapeutic areas, and suitable for a focused internship.

IMMUNOLOGY

Priority areas: Autoimmune and immune-mediated diseases, particularly rheumatology, neuro-immunology and dermatology; primary and secondary immunodeficiency.

Illustrative research opportunities

- Disease mechanisms, immune pathways and drivers of heterogeneity
- Biomarkers for diagnosis, prognosis, activity or treatment response
- Patient stratification and identification of therapy-responsive subgroups
- Novel targets, translational models and evidence supporting clinical development

HEMATOLOGY

Priority areas: Congenital bleeding disorders, including Hemophilia A, Hemophilia B and von Willebrand disease; thrombolysis and acute thrombosis; myeloproliferative neoplasms; iron metabolism; and differentiated opportunities in sickle cell disease.

Illustrative research opportunities

- Breakthrough or durable treatment strategies for bleeding disorders
- Prevention or management of bleeding and thrombotic events
- Molecular or clinical heterogeneity in myeloproliferative neoplasms
- Novel biomarkers, endpoints and evidence-generation approaches

RENAL & CARDIOVASCULAR

Priority areas: Rare renal diseases, including Alport syndrome, autosomal dominant polycystic kidney disease, anti-neutrophil cytoplasmic antibody-associated vasculitis and focal segmental glomerulosclerosis; high cardiovascular-risk populations; and rare cardiovascular diseases.

Illustrative research opportunities

- Mechanisms and markers of disease progression or organ injury
- Risk stratification for major adverse cardiovascular events in kidney disease and post-revascularization peripheral artery disease
- Rare cardiomyopathies and cardiac sarcoidosis
- Clinical, biomarker or real-world approaches to improve trial design and patient selection
- Strategies to target therapeutics to kidney and heart

IMMUNOGLOBULINS

Priority areas: Primary and secondary immunodeficiency disorders, with emphasis on improving immunoglobulin treatment and patient outcomes.

Illustrative research opportunities

- Treatment optimization, dosing, administration and response variability
- Predictors of effectiveness, safety and treatment burden
- Patient-centered outcomes, quality of life and healthcare utilization
- Real-world evidence to characterize care pathways and unmet need

CROSS-CUTTING METHODS AND THEMES

Biomarkers & precision medicine	**Patient stratification**	**Disease mechanisms**	**Novel therapeutic approaches**
Clinical & real-world evidence	**Translational research**	**Advanced analytics, artificial intelligence & data science**	**Clear patient impact**

BUSINESS USE